Breast Cancer Trial, Recruiting NCT05817227 Sponsor: National Cancer Institute, Naples Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05817227
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women diagnosed with triple-negative breast cancer (a specific type of breast cancer) who have not yet received any drug treatment for it
  • Healthy women between the ages of 25 and 60 (confirm with trial site for the exact role of healthy participants in this trial)

Who may not be able to join:

  • People who have diabetes
  • People who have high blood pressure
  • People with an active infection of any kind
  • People who have HIV
  • People who have Hepatitis B or Hepatitis C
  • People with long-term inflammatory conditions
  • People who currently have or have previously had any form of cancer
  • People with heart disease
  • People who are currently taking any medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alfredo Budillon, M.D., IRCCS I.N.T. "G. Pascale"

Phone: 08117770584

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National Cancer Institute, Naples
Registry
ClinicalTrials.gov
Start date
19 May 2022
Est. completion
19 November 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Use of immunohistochemistry investigation (IHC); Prospective evaluation of expression of some selenoproteins by kit ELISA in plasma samples

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov